Skip to main content

Table 1 Patient demographics and clinical characteristics

From: The relationship of systemic inflammation to prior hospitalization in adult patients with cystic fibrosis

  Total
(n = 58)
FEV1% predicted
≥ median
(n = 29)
FEV1% predicted
< median
(n = 29)
P-value
Age, years range 18 - 61 18 - 49 19 - 61 < 0.01
Sex, male n (%) 34 (58.62) 18 (62.1) 16 (55.2) 0.79
BMI, kg/m2 ± SD 23.24 ± 3.25 24.2 ± 3.4 22.3 ± 2.9 0.02
FEV1, % predicted ± SD 71.93 ± 24.80 92.9 ± 12.9 51.0 ± 13.2 -
Current medications     
   Azithromycin, n (%) 18 (31.03) 3 (10.3) 15 (51.7) < 0.01
   Ciprofloxacin, n (%) 2 (3.45) 1 (3.4) 1 (3.4) 1.00
   Dornase alfa, n (%) 24 (41.38) 11 (37.9) 13 (44.8) 0.79
   Ibuprofen, n (%) 2 (3.45) 2 (6.9) 0 (0) 0.49
   Prednisone, n (%) 0 (0) 0 (0) 0 (0) -
   Tobramycin, n (%) 13 (22.41) 2 (6.9) 11 (37.9) 0.01
   Inhaled steroids, n (%) 37 (63.79) 15 (51.7) 22 (75.9) 0.10
Diabetes, n (%) 22 (37.93) 10 (34.5) 12 (41.4) 0.79
Hospitalization, n (%) 21 (36.2) 6 (20.7) 15 (51.7) 0.03
Pseudomonas, n (%) 42 (72.41) 15 (51.7) 27 (93.1) < 0.01